| Christina Galindo Cantu, | |
|
1055 E Main St, Alice, TX 78332-5044 | |
| (361) 664-2498 | |
| Not Available |
| Full Name | Christina Galindo Cantu |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1055 E Main St, Alice, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023339207 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 44405 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Christina Galindo Cantu, 1055 E Main St, Alice, TX 78332-5044 Ph: (361) 664-2498 | Christina Galindo Cantu, 1055 E Main St, Alice, TX 78332-5044 Ph: (361) 664-2498 |
News Archive
Modern Healthcare reports on the many companies that are lining up to play a role in the services, marketing and other related ventures to support accountable care organizations. Meanwhile, Politico Pro reports on a poll released Monday that shows support for the health law's individual mandate is growing.
New data regarding hospital readmission rates have emerged "amid a national debate over how to reduce" these numbers, "which cost the federal government billions of dollars a year in Medicare reimbursements," the New York Times reports.
The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.
Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that Phase IIb data for its lead drug candidate Soluble Ferric Pyrophosphate (SFP) have been accepted for presentation at the XLVII European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, organized in collaboration with the Deutsche Gesellschaft fur Nephrologie (DGfN) in Munich, Germany, June 25-28, 2010.
Inhibitex, today reported positive preliminary interim safety and antiviral data from the first two monotherapy cohorts of its ongoing Phase 1b clinical trial of INX-189, an oral NS5b nucleotide inhibitor being developed to treat chronic infections caused by hepatitis C virus.
› Verified 4 days ago
Elizabeth Hernandez, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1115 E Main St, Alice, TX 78332 Phone: 361-664-1344 | |
Dr. Daniel Isreal Garcia, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1055 E Main St, Alice, TX 78332 Phone: 361-664-2498 Fax: 361-396-0219 | |
Victorine Chi, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2701 E Main St, Alice, TX 78332 Phone: 361-668-0504 | |
Karen Eliza Amacio, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1055 E Main St, Alice, TX 78332 Phone: 361-664-2498 | |
Larry E. Garza, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1115 E Main St, Alice, TX 78332 Phone: 361-664-6262 Fax: 361-668-4920 | |
Morgan Kay Osborn, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1115 E Main St, Alice, TX 78332 Phone: 361-664-1344 Fax: 361-668-4920 |